Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism.
Previously undescribed molecular mechanisms of resistance will emerge with the increased use of cyclin-dependent kinase 4/6 inhibitors in clinical settings. To identify genomic aberrations in circulating tumor DNA associated with treatment resistance in palbociclib-treated metastatic breast cancer (MBC) patients, we collected 35 pre- and post-treatment blood samples from 16 patients with estrogen receptor-positive (ER
Abu-Khalaf, M., Wang, C., Zhang, Z., Luo, R., Chong, W., Silver, D., Fellin, F., Jaslow, R., Lopez, A., Cescon, T., Jiang, W., Myers, R., Wei, Q., Li, B., Cristofanilli, M., & Yang, H. (2022). Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism.. Cancers (Basel), 14 (12), 2872. https://doi.org/https://doi.org/10.3390%2Fcancers14122872